Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2020-06-04 Regulatory Filings
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Genmab Announces European Marketing Authorization for the Subcutaneous Formulation of DARZALEX® (daratumumab) for the Treatment of Patients with Multiple Myeloma
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' from Genmab regarding the European marketing authorization for a specific drug formulation (DARZALEX). It provides details on the regulatory approval, the clinical studies (COLUMBA and PLEIADES) supporting it, and background information on the company's product pipeline. It does not constitute a full financial report, audit, or proxy statement. As it is a standard regulatory announcement of a corporate development, it falls under the 'Regulatory Filings' category.
2020-06-04 English
Regulatory Filings 2020
Regulatory Filings Classification · 100% confidence The document is a formal announcement from Genmab A/S, dated June 4, 2020, detailing the European Marketing Authorization for a subcutaneous formulation of DARZALEX®. It highlights key clinical trial data (COLUMBA, PLEIADES) and provides extensive background on the drug and the company's pipeline and technology platforms. This content structure—a press release announcing a significant regulatory/product milestone, including clinical context and company boilerplate—is characteristic of an Earnings Release (ER) or a general corporate announcement. Since it is not a full annual report (10-K), a quarterly report (IR), a transcript (CT), or a specific shareholder vote document, and it focuses on a major business/product development, it fits best as an Earnings Release (ER) if it were tied to a reporting period, or a general Regulatory Filing (RNS) if it's purely a regulatory update. Given the nature of announcing a major regulatory approval (Marketing Authorization) which is a key business event, and the format being a standard press release, 'ER' is often used for major positive news releases, but 'RNS' (Regulatory Filings/Announcements) is the most accurate general category for non-financial period-end regulatory milestones that aren't explicitly covered elsewhere. However, since this is a major product/regulatory achievement announcement, and not a standard quarterly financial summary, it is best classified as a general Regulatory Filing (RNS) as it is a formal announcement of a regulatory event.
2020-06-04 English
6-K
Foreign Filer Report
2020-06-03 English
6-K
Foreign Filer Report
2020-05-28 English
Genmab Announces Positive Topline Results in Phase III ANDROMEDA Study of Daratumumab in Light-chain (AL) Amyloidosis
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' from Genmab regarding positive topline results from a Phase III clinical trial (ANDROMEDA study). It details the study's primary endpoints, safety profile, and future regulatory implications. It does not constitute a full financial report, a transcript, or a governance document. As it is a standard corporate announcement regarding clinical trial outcomes, it falls under the 'Regulatory Filings' (RNS) category, which serves as the fallback for general corporate announcements that do not fit into more specific categories like Earnings Releases (which focus on financial results) or M&A activity.
2020-05-28 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is titled "Genmab Announces Positive Topline Results in Phase III ANDROMEDA Study of Daratumumab..." and contains key clinical trial results (Phase III endpoint met, safety profile). It is a formal announcement detailing clinical progress and mentioning that Janssen "will discuss data with health authorities to prepare for regulatory filings." This structure—announcing key results from a trial and mentioning next steps toward filing—is characteristic of an Earnings Release (ER) or a general announcement related to clinical progress. Since it focuses on the immediate release of topline results rather than a comprehensive periodic financial report (10-K or IR), and it is not a transcript (CT) or a formal presentation (IP), the best fit among the provided options is Earnings Release (ER), as these announcements often contain the most critical, immediate financial/operational news, which clinical trial success is for a biotech company. It is not a Report Publication Announcement (RPA) because it contains the substantive results, not just a notice that a report is available.
2020-05-28 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.